TY - JOUR
T1 - Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma
T2 - a Retrospective Cohort Study
AU - Furtado, Felipe S.
AU - Ferrone, Cristina R.
AU - Lee, Susanna I.
AU - Vangel, Mark
AU - Rosman, David A.
AU - Weekes, Colin
AU - Qadan, Motaz
AU - Fernandez-Del Castillo, Carlos
AU - Ryan, David P.
AU - Blaszkowsky, Lawrence S.
AU - Hong, Theodore S.
AU - Clark, Jeffrey W.
AU - Striar, Robin
AU - Groshar, David
AU - Cañamaque, Lina G.
AU - Umutlu, Lale
AU - Catalano, Onofrio A.
N1 - Publisher Copyright:
© 2021, World Molecular Imaging Society.
PY - 2021/6
Y1 - 2021/6
N2 - Purpose: Imaging is central to the diagnosis and management of Pancreatic Ductal Adenocarcinoma (PDAC). This study evaluated if positron emission tomography (PET)/magnetic resonance imaging (MRI) elicited treatment modifications in PDAC when compared to standard of care imaging (SCI). Procedures: This retrospective study included consecutive patients with PDAC who underwent 2-deoxy-2-[18F]fluoro-d-glucose ([18F]F-FDG) PET/MRI and SCI from May 2017 to January 2019. SCI included abdominal computed tomography (CT), MRI, and/or PET/CT. For patients who had more than one pair of PET/MRI and SCI, each management decision was independently evaluated. Treatment strategies based on each modality were extracted from electronic medical records. Follow-up was evaluated until January 2020. Results: Twenty-five patients underwent 37 PET/MRI’s, mean age was 65 ± 9 years and 13 (13/25, 52 %) were men. 49 % (18/37, 95 % CI 33–64 %) of the PET/MRI scans changed clinical management. Whether the SCI included a PET/CT or not did not significantly modify the probability of management change (OR = 0.9, 95 % CI 0.2–4, p = 1). One hundred percent (33/33) of the available follow-up data confirmed PET/MRI findings. Conclusions: PET/MRI significantly changed PDAC management, consistently across the different SCI modalities it was compared to. These findings suggest a role for PET/MRI in the management of PDAC.
AB - Purpose: Imaging is central to the diagnosis and management of Pancreatic Ductal Adenocarcinoma (PDAC). This study evaluated if positron emission tomography (PET)/magnetic resonance imaging (MRI) elicited treatment modifications in PDAC when compared to standard of care imaging (SCI). Procedures: This retrospective study included consecutive patients with PDAC who underwent 2-deoxy-2-[18F]fluoro-d-glucose ([18F]F-FDG) PET/MRI and SCI from May 2017 to January 2019. SCI included abdominal computed tomography (CT), MRI, and/or PET/CT. For patients who had more than one pair of PET/MRI and SCI, each management decision was independently evaluated. Treatment strategies based on each modality were extracted from electronic medical records. Follow-up was evaluated until January 2020. Results: Twenty-five patients underwent 37 PET/MRI’s, mean age was 65 ± 9 years and 13 (13/25, 52 %) were men. 49 % (18/37, 95 % CI 33–64 %) of the PET/MRI scans changed clinical management. Whether the SCI included a PET/CT or not did not significantly modify the probability of management change (OR = 0.9, 95 % CI 0.2–4, p = 1). One hundred percent (33/33) of the available follow-up data confirmed PET/MRI findings. Conclusions: PET/MRI significantly changed PDAC management, consistently across the different SCI modalities it was compared to. These findings suggest a role for PET/MRI in the management of PDAC.
KW - FDG
KW - MRI
KW - Management changes
KW - PET
KW - PET/MRI
KW - Pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=85099224731&partnerID=8YFLogxK
U2 - 10.1007/s11307-020-01569-7
DO - 10.1007/s11307-020-01569-7
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33415677
AN - SCOPUS:85099224731
SN - 1536-1632
VL - 23
SP - 456
EP - 466
JO - Molecular Imaging and Biology
JF - Molecular Imaging and Biology
IS - 3
ER -
